JP2019519527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519527A5 JP2019519527A5 JP2018561639A JP2018561639A JP2019519527A5 JP 2019519527 A5 JP2019519527 A5 JP 2019519527A5 JP 2018561639 A JP2018561639 A JP 2018561639A JP 2018561639 A JP2018561639 A JP 2018561639A JP 2019519527 A5 JP2019519527 A5 JP 2019519527A5
- Authority
- JP
- Japan
- Prior art keywords
- domain monomer
- domain
- construct
- polypeptide
- monomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000178 monomer Substances 0.000 claims 25
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 238000006471 dimerization reaction Methods 0.000 claims 6
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 201000001981 dermatomyositis Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 208000028387 Felty syndrome Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010033661 Pancytopenia Diseases 0.000 claims 1
- 102000015094 Paraproteins Human genes 0.000 claims 1
- 108010064255 Paraproteins Proteins 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010054000 Type II hypersensitivity Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000013564 activation of immune response Effects 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024389 cytopenia Diseases 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 208000033699 familial Guillain-Barre syndrome Diseases 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 210000004789 organ system Anatomy 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000019635 sulfation Effects 0.000 claims 1
- 238000005670 sulfation reaction Methods 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008026 type II hypersensitivity Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022010912A JP2022068176A (ja) | 2016-05-23 | 2022-01-27 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2024193057A JP2025026880A (ja) | 2016-05-23 | 2024-11-01 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340322P | 2016-05-23 | 2016-05-23 | |
| US62/340,322 | 2016-05-23 | ||
| US201762443451P | 2017-01-06 | 2017-01-06 | |
| US62/443,451 | 2017-01-06 | ||
| PCT/US2017/034087 WO2017205436A1 (en) | 2016-05-23 | 2017-05-23 | Compositions and methods related to engineered fc constructs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010912A Division JP2022068176A (ja) | 2016-05-23 | 2022-01-27 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019519527A JP2019519527A (ja) | 2019-07-11 |
| JP2019519527A5 true JP2019519527A5 (enExample) | 2020-07-02 |
Family
ID=60412547
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561639A Withdrawn JP2019519527A (ja) | 2016-05-23 | 2017-05-23 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2018561641A Active JP7045333B6 (ja) | 2016-05-23 | 2017-05-23 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2022010912A Pending JP2022068176A (ja) | 2016-05-23 | 2022-01-27 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2022044109A Active JP7295301B2 (ja) | 2016-05-23 | 2022-03-18 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2024193057A Withdrawn JP2025026880A (ja) | 2016-05-23 | 2024-11-01 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561641A Active JP7045333B6 (ja) | 2016-05-23 | 2017-05-23 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2022010912A Pending JP2022068176A (ja) | 2016-05-23 | 2022-01-27 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2022044109A Active JP7295301B2 (ja) | 2016-05-23 | 2022-03-18 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2024193057A Withdrawn JP2025026880A (ja) | 2016-05-23 | 2024-11-01 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US11155640B2 (enExample) |
| EP (2) | EP3484514B1 (enExample) |
| JP (5) | JP2019519527A (enExample) |
| KR (3) | KR102635635B1 (enExample) |
| CN (4) | CN109789203B (enExample) |
| AU (2) | AU2017272111B2 (enExample) |
| BR (2) | BR112018074056A2 (enExample) |
| CA (2) | CA3025306A1 (enExample) |
| DK (1) | DK3484514T3 (enExample) |
| ES (1) | ES2973251T3 (enExample) |
| IL (3) | IL263211B2 (enExample) |
| NZ (2) | NZ749292A (enExample) |
| PL (1) | PL3484514T3 (enExample) |
| SG (3) | SG11201810466PA (enExample) |
| WO (2) | WO2017205436A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106661125B (zh) | 2014-05-02 | 2021-10-01 | 动量制药公司 | 涉及工程化Fc构建体的组合物和方法 |
| US12391759B2 (en) | 2016-03-02 | 2025-08-19 | Momenta Pharmaceuticals, Inc. | Methods related to engineered Fc constructs |
| KR102635635B1 (ko) * | 2016-05-23 | 2024-02-14 | 모멘타 파머슈티컬스 인코포레이티드 | 유전자 조작 Fc 작제물에 관한 조성물 및 방법 |
| CN110650748B (zh) | 2017-01-06 | 2024-01-02 | 动量制药公司 | 与经工程改造的Fc构建体相关的组合物和方法 |
| CN113164592A (zh) * | 2018-07-11 | 2021-07-23 | 动量制药公司 | 与工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
| CA3106207A1 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4 |
| CN112996910A (zh) * | 2018-07-11 | 2021-06-18 | 动量制药公司 | 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
| CA3106254A1 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
| US20250346676A1 (en) * | 2018-07-11 | 2025-11-13 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CCR4 |
| BR112021000392A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados |
| CA3106142A1 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 |
| BR112021000415A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados |
| KR102661494B1 (ko) | 2019-03-08 | 2024-04-29 | 에이치엘만도 주식회사 | 랙구동형 동력 보조 조향장치 |
| KR20220062084A (ko) | 2019-09-13 | 2022-05-13 | 체에스엘 베링 렝나우 아게 | 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체 |
| JP2023505493A (ja) * | 2019-12-06 | 2023-02-09 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | Ｆｃ多量体の安定組成物 |
| CN111808170A (zh) * | 2020-06-29 | 2020-10-23 | 江苏为真生物医药技术股份有限公司 | 多肽、hla-dr蛋白及其制备方法和应用 |
| WO2022125355A1 (en) * | 2020-12-07 | 2022-06-16 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use |
| WO2024206820A1 (en) * | 2023-03-30 | 2024-10-03 | Dna Twopointo, Inc. | Fc engineering for heterodimeric antibody format |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2556219B1 (fr) | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
| US5426641A (en) | 1994-01-28 | 1995-06-20 | Bell Communications Research, Inc. | Adaptive class AB amplifier for TDMA wireless communications systems |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AU3804397A (en) | 1996-06-14 | 1998-01-07 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| US20090074839A1 (en) | 1997-01-22 | 2009-03-19 | Marton Milankovits | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications |
| US7951917B1 (en) * | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2001045746A2 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| WO2008088422A2 (en) | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
| BRPI0620639A2 (pt) | 2006-12-21 | 2011-11-22 | Micromet Ag | anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos |
| US20080260738A1 (en) | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
| BRPI0811857A2 (pt) | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
| EP2185589B1 (en) | 2007-06-01 | 2016-01-06 | University of Maryland, Baltimore | Immunoglobulin constant region fc receptor binding agents |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| SG189730A1 (en) | 2008-04-02 | 2013-05-31 | Macrogenics Inc | Her2/neu-specific antibodies and methods of using same |
| WO2010042481A1 (en) | 2008-10-06 | 2010-04-15 | University Of Chicago | Compositions and methods related to bacterial eap, emp, and/or adsa proteins |
| US20100143353A1 (en) | 2008-12-04 | 2010-06-10 | Mosser David M | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME |
| CA2747011C (en) | 2008-12-18 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Nkg2d-fc for immunotherapy |
| AU2010206681A1 (en) | 2009-01-23 | 2011-09-01 | Biogen Idec Ma Inc. | Stabilized Fc polypeptides with reduced effector function and methods of use |
| EP2432803A2 (en) | 2009-05-20 | 2012-03-28 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
| WO2010135534A2 (en) | 2009-05-20 | 2010-11-25 | Children's Medical Center Corporation | Compositions for the treatment of metastatic cancer and methods of use thereof |
| JP5683581B2 (ja) | 2009-06-30 | 2015-03-11 | リサーチ ディベロップメント ファウンデーション | 免疫グロブリンＦｃポリペプチド |
| CA2781519A1 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| KR101808602B1 (ko) | 2009-10-07 | 2017-12-13 | 마크로제닉스, 인크. | 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법 |
| EP2504360B1 (en) | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| GB0922209D0 (en) | 2009-12-18 | 2010-02-03 | Univ Nottingham | Proteins, nucleic acid molecules and compositions |
| JP6200806B2 (ja) | 2010-05-21 | 2017-09-20 | メリマック ファーマシューティカルズ インコーポレーティッド | 二重特異的融合タンパク質 |
| WO2012006635A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Processable single chain molecules and polypeptides made using same |
| MX368531B (es) | 2010-07-28 | 2019-10-07 | Gliknik Inc | Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente. |
| US20130177555A1 (en) | 2010-08-13 | 2013-07-11 | Medimmune Limited | Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| CA2822366A1 (en) * | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| BR112013023653A2 (pt) | 2011-03-17 | 2016-12-13 | Univ Ramot | anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica |
| SG10201602371VA (en) | 2011-03-25 | 2016-04-28 | Glenmark Pharmaceuticals Sa | Hetero-dimeric immunoglobulins |
| KR102052774B1 (ko) * | 2011-11-04 | 2019-12-04 | 자임워크스 인코포레이티드 | Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계 |
| CA2875246A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Procoagulant compounds |
| WO2013192131A1 (en) * | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
| WO2014031646A2 (en) | 2012-08-20 | 2014-02-27 | Gliknik Inc. | Molecules with antigen binding and polyvalent fc gamma receptor binding activity |
| CN110894231A (zh) | 2012-10-17 | 2020-03-20 | 康诺贝林伦瑙有限公司 | 免疫调节蛋白 |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| CN104558194B (zh) | 2013-10-17 | 2018-04-27 | 泰州迈博太科药业有限公司 | 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途 |
| CN106029087A (zh) * | 2013-12-20 | 2016-10-12 | 印第安纳大学研究及科技有限公司 | 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽 |
| BR112016016416A2 (pt) | 2014-01-15 | 2017-10-03 | Hoffmann La Roche | VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS |
| CA2931979A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding properties |
| AU2015226101B2 (en) | 2014-03-05 | 2019-08-22 | Ucb Biopharma Sprl | Multimeric Fc proteins |
| BR112016020368A2 (pt) | 2014-03-05 | 2018-01-23 | Ucb Biopharma Sprl | proteínas fc multiméricas |
| AU2015248785A1 (en) | 2014-04-16 | 2016-11-24 | Ucb Biopharma Sprl | Multimeric Fc proteins |
| CN106661125B (zh) | 2014-05-02 | 2021-10-01 | 动量制药公司 | 涉及工程化Fc构建体的组合物和方法 |
| NZ726520A (en) | 2014-05-29 | 2018-12-21 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| US12391759B2 (en) | 2016-03-02 | 2025-08-19 | Momenta Pharmaceuticals, Inc. | Methods related to engineered Fc constructs |
| KR102635635B1 (ko) | 2016-05-23 | 2024-02-14 | 모멘타 파머슈티컬스 인코포레이티드 | 유전자 조작 Fc 작제물에 관한 조성물 및 방법 |
| CN110650748B (zh) * | 2017-01-06 | 2024-01-02 | 动量制药公司 | 与经工程改造的Fc构建体相关的组合物和方法 |
-
2017
- 2017-05-23 KR KR1020227037780A patent/KR102635635B1/ko active Active
- 2017-05-23 BR BR112018074056-0A patent/BR112018074056A2/pt active Search and Examination
- 2017-05-23 PL PL17803463.3T patent/PL3484514T3/pl unknown
- 2017-05-23 IL IL263211A patent/IL263211B2/en unknown
- 2017-05-23 CA CA3025306A patent/CA3025306A1/en active Pending
- 2017-05-23 SG SG11201810466PA patent/SG11201810466PA/en unknown
- 2017-05-23 JP JP2018561639A patent/JP2019519527A/ja not_active Withdrawn
- 2017-05-23 US US16/303,793 patent/US11155640B2/en active Active
- 2017-05-23 SG SG11201810465RA patent/SG11201810465RA/en unknown
- 2017-05-23 ES ES17803463T patent/ES2973251T3/es active Active
- 2017-05-23 JP JP2018561641A patent/JP7045333B6/ja active Active
- 2017-05-23 NZ NZ749292A patent/NZ749292A/en unknown
- 2017-05-23 CA CA3025310A patent/CA3025310A1/en active Pending
- 2017-05-23 SG SG10202011624SA patent/SG10202011624SA/en unknown
- 2017-05-23 NZ NZ749279A patent/NZ749279A/en unknown
- 2017-05-23 AU AU2017272111A patent/AU2017272111B2/en active Active
- 2017-05-23 CN CN201780045710.8A patent/CN109789203B/zh active Active
- 2017-05-23 CN CN202410270902.0A patent/CN118206639A/zh active Pending
- 2017-05-23 DK DK17803463.3T patent/DK3484514T3/da active
- 2017-05-23 BR BR112018074032-2A patent/BR112018074032A2/pt unknown
- 2017-05-23 WO PCT/US2017/034087 patent/WO2017205436A1/en not_active Ceased
- 2017-05-23 IL IL309293A patent/IL309293A/en unknown
- 2017-05-23 CN CN202210924611.XA patent/CN116063540A/zh active Pending
- 2017-05-23 KR KR1020187037345A patent/KR102590061B1/ko active Active
- 2017-05-23 AU AU2017272109A patent/AU2017272109B2/en active Active
- 2017-05-23 EP EP17803463.3A patent/EP3484514B1/en active Active
- 2017-05-23 IL IL263213A patent/IL263213B2/en unknown
- 2017-05-23 US US16/303,831 patent/US11623964B2/en active Active
- 2017-05-23 KR KR1020187037334A patent/KR102462084B1/ko active Active
- 2017-05-23 EP EP17803465.8A patent/EP3464376A4/en active Pending
- 2017-05-23 CN CN201780045688.7A patent/CN109963869A/zh active Pending
- 2017-05-23 WO PCT/US2017/034084 patent/WO2017205434A1/en not_active Ceased
-
2021
- 2021-10-01 US US17/491,677 patent/US12297291B2/en active Active
-
2022
- 2022-01-27 JP JP2022010912A patent/JP2022068176A/ja active Pending
- 2022-03-18 JP JP2022044109A patent/JP7295301B2/ja active Active
-
2023
- 2023-04-10 US US18/298,131 patent/US20240067757A1/en active Pending
-
2024
- 2024-11-01 JP JP2024193057A patent/JP2025026880A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519527A5 (enExample) | ||
| JP7496091B2 (ja) | 合理的に設計された新規なタンパク質組成物 | |
| HRP20191334T1 (hr) | Anti-fcrn antitijela | |
| Lim et al. | Structural biology of the TNFα antagonists used in the treatment of rheumatoid arthritis | |
| Monnet et al. | Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions | |
| JP2011526792A5 (enExample) | ||
| JP2020501550A5 (enExample) | ||
| JP2019520797A5 (enExample) | ||
| HRP20192006T1 (hr) | Antitijela specifična za fcrn | |
| TWI797124B (zh) | 抗干擾素-γ之抗體及其應用 | |
| JP2018512145A5 (enExample) | ||
| JP2019515652A5 (enExample) | ||
| JP2014508759A5 (enExample) | ||
| CN104968675A (zh) | 识别mhc ii类限制性mage-a3的t细胞受体 | |
| Taylor et al. | Avian IgY binds to a monocyte receptor with IgG-like kinetics despite an IgE-like structure | |
| JP2022542543A (ja) | 抗ｄｌｌ３キメラ抗原受容体及びその使用 | |
| CA2977010A1 (en) | Fc mutants with modified functional activity | |
| Frank et al. | CD8-Specific designed ankyrin repeat proteins improve selective gene delivery into human and primate T lymphocytes | |
| CN108473571A (zh) | 结合人Fc受体的融合蛋白 | |
| Wang et al. | Enhancement of antibody functions through Fc multiplications | |
| CN117616050A (zh) | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 | |
| JP2020532969A5 (enExample) | ||
| Klaus et al. | CH2 domain of mouse IgG3 governs antibody oligomerization, increases functional affinity to multivalent antigens and enhances hemagglutination | |
| PE20191662A1 (es) | Anticuerpos anti-il-5 | |
| Richter et al. | Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc |